Sanofi Completes the Acquisition of Dynavax
February 11, 2026
February 11, 2026
PARIS, France, Feb. 11 -- Sanofi, a life sciences company, issued the following news release on Feb. 10, 2026:
* * *
Sanofi completes the acquisition of Dynavax
Sanofi today announced that it has completed theacquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax's adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also include . . .
* * *
Sanofi completes the acquisition of Dynavax
Sanofi today announced that it has completed theacquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax's adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also include . . .